Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Apr 16, 2022; 10(11): 3389-3400
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3389
Table 1 Demographics and baseline characteristics of the breast cancer patients undergoing neoadjuvant chemotherapy
Variables
Dummy variables
Training cohort
Testing cohort
Overall (n = 287)
Yes (n = 255)
No (n = 32)
P value
Overall (n = 200)
Yes (n = 176)
No (n = 24)
P value
Age [median (IQR)],yr61.00 (55.00, 70.00)61.00 (54.00, 70.00)64.00 (58.75, 69.25)0.1161.00 (55.75, 70.25)61.00 (55.00, 70.25)64.00 (57.75, 70.25)0.28
Menopausal (%)Yes35 (12.2)30 (11.8)5 (15.6)0.7328 (14.0)24 (13.6)4 (16.7)0.93
No252 (87.8)225 (88.2)27 (84.4)172 (86.0)152 (86.4)20 (83.3)
T stage (%)T1-2216 (75.3)196 (76.9)20 (62.5)0.12156 (78.0)140 (79.5)16 (66.7)0.24
T3-471 (24.7)59 (23.1)12 (37.5)44 (22.0)36 (20.5)8 (33.3)
N stage (%)N0-171 (24.7)58 (22.7)13 (40.6)0.0452 (26.0)40 (22.7)12 (50.0)0.01
N2-3216 (75.3)197 (77.3)19 (59.4)148 (74.0)136 (77.3)12 (50.0)
Grade (%)I-II195 (67.9)175 (68.6)20 (62.5)0.61134 (67.0)118 (67.0)16 (66.7)0.11
III92 (32.1)80 (31.4)12 (37.5)66 (33.0)58 (33.0)8 (33.3)
Histology (%)IDC111 (38.7)106 (41.6)5 (15.6)0.0280 (40.0)77 (43.8)3 (12.5)0.03
ILC91 (31.7)79 (31.0)12 (37.5)61 (30.5)51 (29.0)10 (41.7)
IMC48 (16.7)41 (16.1)7 (21.9)36 (18.0)29 (16.5)7 (29.2)
Others37 (12.9)29 (11.4)8 (25.0)23 (11.5)19 (10.8)4 (16.7)
Molecular subtyping (%)HER2-LuB108 (37.6)100 (39.2)8 (25.0)< 0.0176 (38.0)71 (40.3)5 (20.8)0.01
HER2+71 (24.7)66 (25.9)5 (15.6)53 (26.5)50 (28.4)3 (12.5)
HER2+LuB29 (10.1)24 (9.4)5 (15.6)18 (9.0)15 (8.5)3 (12.5)
LuA54 (18.8)41 (16.1)13 (40.6)37 (18.5)25 (14.2)12 (50.0)
TN25 (8.7)24 (9.4)1 (3.1)16 (8.0)15 (8.5)1 (4.2)
BMI (%)≤ 1821 (7.3)21 (8.2)0 (0.0)0.2211 (5.5)11 (6.2)0 (0.0)0.42
≥ 2736 (12.5)31 (12.2)5 (15.6)27 (13.5)23 (13.1)4 (16.7)
18 - 27230 (80.1)203 (79.6)27 (84.4)162 (81.0)142 (80.7)20 (83.3)
Smoking (%)No258 (89.9)231 (90.6)27 (84.4)0.43182 (91.0)161 (91.5)21 (87.5)0.79
Yes29 (10.1)24 (9.4)5 (15.6)18 (9.0)15 (8.5)3 (12.5)
ER (%)Negative103 (35.9)91 (35.7)12 (37.5)0.9973 (36.5)66 (37.5)7 (29.2)0.56
Positive184 (64.1)164 (64.3)20 (62.5)127 (63.5)110 (62.5)17 (70.8)
PR (%)Negative165 (57.5)141 (55.3)24 (75.0)0.05109 (54.5)91 (51.7)18 (75.0)0.05
Positive122 (42.5)114 (44.7)8 (25.0)91 (45.5)85 (48.3)6 (25.0)
HER2 (%)Negative157 (54.7)140 (54.9)17 (53.1)0.99110 (55.0)96 (54.5)14 (58.3)0.89
Positive130 (45.3)115 (45.1)15 (46.9)90 (45.0)80 (45.5)10 (41.7)
PLT [median (IQR)] × 109/L200.00 (154.50, 268.50)187.00 (152.50, 245.50)388.00 (334.50, 454.00)< 0.01202.50 (158.75, 267.25)190.50 (154.00, 246.50)377.00 (332.50, 443.50)< 0.01
Neutrophil [median (IQR)] × 109/L4.35 (3.52, 5.13)4.54 (3.76, 5.23)3.09 (2.02, 3.39)< 0.014.44 (3.50, 5.21)4.60 (3.78, 5.27)3.09 (2.02, 3.35)< 0.01
MONO [median (IQR)] × 109/L0.40 (0.25, 0.57)0.38 (0.24, 0.50)0.88 (0.80, 0.94)< 0.010.41 (0.25, 0.58)0.37 (0.23, 0.49)0.86 (0.75, 0.91)< 0.01
Lymphocyte [median (IQR)] × 109/L3.09 (2.92, 3.30)3.13 (2.96, 3.32)1.64 (1.14, 2.16)< 0.013.08 (2.92, 3.30)3.12 (2.98, 3.32)1.67 (1.14, 2.16)< 0.01
NLR [median (IQR)]1.43 (1.20, 1.67)1.42 (1.20, 1.64)1.56 (1.21, 2.68)0.031.48 (1.20, 1.70)1.47 (1.20, 1.67)1.56 (1.22, 2.75)< 0.01
LMR [median (IQR)]7.62 (5.59, 12.96)8.51 (6.18, 13.31)1.86 (1.51, 2.47)< 0.017.59 (5.60, 13.07)8.53 (6.26, 13.46)1.87 (1.59, 2.52)< 0.01
PLR [median (IQR)]64.45 (49.59, 85.43)61.99 (47.81, 78.50)237.76 (189.53, 342.96)< 0.0165.33 (50.30, 85.89)62.36 (49.02, 78.10)226.10 (189.53, 305.51)< 0.01
ALB [median (IQR)],g/L47.00 (39.00, 55.00)48.00 (41.00, 56.00)32.50 (27.50, 37.00)< 0.0147.00 (39.00, 55.25)49.00 (41.00, 56.00)31.50 (27.50, 37.00)< 0.01
GLB [median (IQR)],g/L23.00 (20.00, 26.00)22.00 (20.00, 25.00)35.00 (30.75, 41.00)< 0.0123.00 (20.00, 26.00)23.00 (20.00, 25.00)35.50 (30.75, 41.25)< 0.01
A/G [median (IQR)]2.11 (1.76, 2.53)2.18 (1.88, 2.57)0.88 (0.82, 1.03)< 0.012.11 (1.71, 2.50)2.18 (1.85, 2.55)0.88 (0.82, 1.03)< 0.01
LDL [median (IQR)],mmol/L3.00 (2.88, 3.10)2.97 (2.87, 3.08)3.13 (3.05, 3.24)< 0.013.00 (2.90, 3.08)2.97 (2.88, 3.07)3.13 (3.04, 3.22)< 0.01
HDL [median (IQR)],mmol/L1.26 (1.19, 1.33)1.29 (1.20, 1.34)1.17 (1.08, 1.20)< 0.011.25 (1.18, 1.32)1.28 (1.20, 1.33)1.15 (1.08, 1.19)0.02
TC [median (IQR)], mmol/L0.52 (0.49, 0.56)0.52 (0.48, 0.56)0.56 (0.52, 0.58)< 0.010.52 (0.48, 0.56)0.52 (0.48, 0.56)0.56 (0.52, 0.57)< 0.01
TG [median (IQR)], mmol/L1.82 (1.61, 2.15)1.78 (1.59, 2.04)2.34 (2.27, 2.39)< 0.011.85 (1.60, 2.15)1.79 (1.59, 2.04)2.34 (2.27, 2.39)< 0.01
Table 2 Performance for response to neoadjuvant chemotherapy risk prediction of models in breast cancer patients
Model
AUC (95%CI)
Sensitivity
Specificity
PPV
NPV
Kappa
Brier
SVM0.96 (0.91-1.01)96.5845.2888.6375.000.680.06
RF0.94 (0.87-1.01)94.4468.7586.6768.750.650.07
NB0.86 (0.79-0.93)96.3635.8083.1475.000.620.07
NN0.88 (0.82-0.94)93.1525.0093.1553.150.620.07
DT0.83 (0.77-0.89)94.5024.1474.1265.630.590.07
GLM0.81 (0.71-0.91)95.7023.7669.8075.000.570.08